Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy

NCT07358195 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07358195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07358195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
February 4, 2026
Completion date
December 31, 2031
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic cancer, kidney failure chronic, stem cell transplant, stem cell transplant complications, tolerance